Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis. The company is also developing and sotatercept for the treatment of patients with pulmonary arterial hypertension. In addition, the company is developing ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease; and ACE-2494, which is in Phase I clinical trials for the treatment of systemic muscle disorders. It has a collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone617-649-9200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$13.99 million
Profitability
Miscellaneous
Employees173
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Acceleron Pharma (NASDAQ:XLRN) Frequently Asked Questions
What is Acceleron Pharma's stock symbol?
Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."
How were Acceleron Pharma's earnings last quarter?
Acceleron Pharma Inc (NASDAQ:XLRN) released its quarterly earnings data on Wednesday, February, 27th. The biopharmaceutical company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.68) by $0.07. The biopharmaceutical company earned $3.80 million during the quarter, compared to analyst estimates of $3.21 million. Acceleron Pharma had a negative net margin of 849.62% and a negative return on equity of 36.63%. The business's revenue for the quarter was up 2.7% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.62) earnings per share. View Acceleron Pharma's Earnings History.
When is Acceleron Pharma's next earnings date?
What price target have analysts set for XLRN?
8 Wall Street analysts have issued 12 month target prices for Acceleron Pharma's stock. Their predictions range from $40.00 to $78.00. On average, they expect Acceleron Pharma's stock price to reach $60.6250 in the next twelve months. This suggests a possible upside of 37.3% from the stock's current price. View Analyst Price Targets for Acceleron Pharma.
What is the consensus analysts' recommendation for Acceleron Pharma?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acceleron Pharma in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Acceleron Pharma.
Has Acceleron Pharma been receiving favorable news coverage?
News articles about XLRN stock have been trending somewhat negative recently, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Acceleron Pharma earned a news sentiment score of -1.5 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near future.
Who are some of Acceleron Pharma's key competitors?
Some companies that are related to Acceleron Pharma include Qiagen (QGEN), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Spark Therapeutics (ONCE), argenx (ARGX), Ablynx (ABLYF), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Repligen (RGEN), Regenxbio (RGNX), Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI) and Crispr Therapeutics (CRSP).
What other stocks do shareholders of Acceleron Pharma own?
Who are Acceleron Pharma's key executives?
Acceleron Pharma's management team includes the folowing people:
- Mr. Habib J. Dable, CEO, Pres & Director (Age 50)
- Dr. Thomas P. Maniatis, Co-Founder, Member of Scientific Advisory Board & Director (Age 76)
- Mr. Kevin F. McLaughlin, Sr. VP, CFO & Treasurer (Age 63)
- Dr. Ravindra Kumar, Chief Scientific Officer & Sr. VP (Age 59)
- Dr. John D. Quisel, Exec. VP, Chief Bus. Officer & Sec. (Age 48)
Who are Acceleron Pharma's major shareholders?
Acceleron Pharma's stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), BlackRock Inc. (9.59%), Westfield Capital Management Co. LP (2.80%), Great Point Partners LLC (2.24%), Perceptive Advisors LLC (1.96%) and Eagle Asset Management Inc. (1.90%). Company insiders that own Acceleron Pharma stock include Christopher Rovaldi, Corp /De/ Celgene, Habib J Dable, Jean George, John D Quisel, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar and Richard F Pops. View Institutional Ownership Trends for Acceleron Pharma.
Which institutional investors are selling Acceleron Pharma stock?
XLRN stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Brown Advisory Inc., Sectoral Asset Management Inc, American Century Companies Inc., Asymmetry Capital Management L.P., Foresite Capital Management III LLC, Barclays PLC and First Trust Advisors LP. Company insiders that have sold Acceleron Pharma company stock in the last year include Habib J Dable, John D Quisel, Kevin F Mclaughlin, Matthew L Sherman and Ravindra Kumar. View Insider Buying and Selling for Acceleron Pharma.
Which institutional investors are buying Acceleron Pharma stock?
XLRN stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Bank of New York Mellon Corp, Great Point Partners LLC, Candriam Luxembourg S.C.A., Westfield Capital Management Co. LP, BlackRock Inc., Fiera Capital Corp and Emory University. View Insider Buying and Selling for Acceleron Pharma.
How do I buy shares of Acceleron Pharma?
Shares of XLRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Acceleron Pharma's stock price today?
One share of XLRN stock can currently be purchased for approximately $44.16.
How big of a company is Acceleron Pharma?
Acceleron Pharma has a market capitalization of $2.28 billion and generates $13.99 million in revenue each year. The biopharmaceutical company earns $-118,870,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis. Acceleron Pharma employs 173 workers across the globe.
What is Acceleron Pharma's official website?
How can I contact Acceleron Pharma?
Acceleron Pharma's mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-9200 or via email at [email protected]
MarketBeat Community Rating for Acceleron Pharma (NASDAQ XLRN)
MarketBeat's community ratings are surveys of what our community members think about Acceleron Pharma and other stocks. Vote "Outperform" if you believe XLRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XLRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
